<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743028</url>
  </required_header>
  <id_info>
    <org_study_id>M10-454</org_study_id>
    <nct_id>NCT00743028</nct_id>
    <nct_alias>NCT00923689</nct_alias>
  </id_info>
  <brief_title>Assess the Oral Bioavailability of New ABT-263 Formulations</brief_title>
  <official_title>A Single Dose Study Evaluating the Oral Bioavailability and Pharmacokinetics of the Capsule Formulation of ABT-263 in Subjects With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multicenter crossover study to determine the oral
      bioavailability of new ABT-263 formulations relative to that of the current ABT-263
      formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable
      subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors
      will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies.</measure>
    <time_frame>Two Period crossover design.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies and assess new ABT-263 formulations after once daily dosing (QD) and twice daily dosing (BID).</measure>
    <time_frame>Three Period crossover design.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measures include number and percentage of subjects having treatment-emergent adverse events tabulated by MedDRA system organ class and preferred term, laboratory test results, lymphocyte enumeration results, vital signs, etc.</measure>
    <time_frame>Two and three period crossover design</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Lymphomas</condition>
  <condition>Leukemias</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.</description>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; or =18 years of age;

          -  Non-hematologic malignancy or hematologic malignancy that is either relapsed or
             refractory to standard therapy, or failed up to 5 prior standard therapies or no know
             effective therapy exists;

          -  Life expectancy is at least 90 days;

          -  If clinically indicated, (e.g., subjects over the age of 70) subjects must have
             documented brain imaging (MRI or CT) negative for subdural or epidural hematoma within
             28 days prior to the 1st dose of study drug;

          -  ECOG performance score of &lt; or = 1;

          -  Adequate bone marrow, renal and hepatic function per local laboratory reference range
             as follows:

               -  ANC &gt; or = 1,000/Âµl;

               -  Platelets &gt; or = 100,000/mm3;

               -  Hemoglobin &gt; or = 9.0 g/dL;

               -  serum creatinine &lt; or = 2.0 mg/dL or calculated creatinine clearance &gt; or = 50;

          -  AST and ALT &lt; or = 3.0 x ULN; Bilirubin &lt; or = 1.5 x ULN. Gilbert's Syndrome may have
             a Bilirubin &gt; 1.5 x ULN;

          -  aPTT, PT not to exceed 1.2 x ULN;

          -  Females must be surgically sterile, postmenopausal, have negative pregnancy test at
             screening;

          -  Females not surgically sterile or postmenopausal &amp; non-vasectomized males must
             practice at least one of the following methods of birth control:

               -  Total abstinence from sexual intercourse (minimum one complete menstrual cycle
                  prior to starting study drug);

               -  Vasectomized partner;

               -  Hormonal contraceptives for at least 3 months prior to study;

               -  Double-barrier method (including condoms, contraceptive sponge, diaphragm or
                  vaginal ring with spermicidal jellies or cream).

        Exclusion Criteria:

          -  History of/clinically suspicious for cancer-related CNS disease; An allogeneic stem
             cell transplant.

          -  Underlying, predisposing condition of bleeding/currently exhibits signs of bleeding.

          -  History of non-chemotherapy induced thrombocytopenic associated bleeding w/i 1 year
             prior to the 1st dose.

          -  Peptic ulcer disease or other hemorrhagic esophagitis/gastritis.

          -  Active ITP/ history of being refractory to platelet transfusions.

          -  Significant history of cardiac, renal, neurologic, psychiatric, endocrinologic,
             metabolic, immunologic/hepatic disease.

          -  Females pregnant or breast-feeding.

          -  History of or active medical condition(s) that affects absorption or motility.

          -  Positive for HIV.

          -  Other clinically significant uncontrolled condition(s) including, but not limited to:
             active systemic fungal infection; neutropenic fever w/i 1 wk prior to study drug.

          -  Steroid therapy w/i 7 days prior to 1st dose for anti-cancer intent.

          -  Anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal
             (except hormones for hypothyroidism or ERT)/agonists required to suppress serum
             testosterone levels [e.g. LHRH, GnRH], any investigational therapy w/i 14 days prior
             to first dose of study drug.

          -  Biologic agent w/i 30 days prior to 1st dose.

          -  Anticoagulation therapy/drugs/herbal supplements affecting platelet function.

          -  Aspirin w/i 7 days prior to 1st dose.

          -  Grapefruit/grapefruit products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10281</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10282</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 16341</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9441</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 20041</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <last_update_submitted>October 6, 2010</last_update_submitted>
  <last_update_submitted_qc>October 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andrew Krivoshik, MD, PhD, Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Other hematological and non-hematological malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

